Agios Pharmaceuticals Inc
Most Recent
Intercept Pharmaceuticals’ Stock Price Rose 17.94% on August 6
On August 6, Intercept Pharmaceuticals’ (ICPT) stock price grew ~17.94% to $114.71—compared to the previous day’s closing price of $97.26.
Why Omeros Stock Rose Last Week
On April 2, 2018, Omeros (OMER) stock opened at $11.12. It grew ~22% over the week to close at $13.58 on April 6.
How Analysts View Agios Pharmaceuticals and Peers in March 2018
Of the nine analysts covering Agios Pharmaceuticals (AGIO) in March 2018, one gave it a “strong buy” rating, and six gave it a “buy” rating.
An Insight into Agios Pharmaceuticals’ Product Pipeline
Agios Pharmaceuticals’ (AGIO) product pipeline includes ivosidenib, which is targeted for mutated IDH1 and AG-881.
Analysts’ Ratings for Athenex and Its Peers in March
Of the six analysts covering Athenex in March 2018, five analysts gave the stock a “buy” rating, while one analyst gave it a “hold” rating.
Analysts’ Recommendations for Bioverativ in January 2018
Fourteen analysts were tracking Bioverativ in January 2018. Four analysts recommended “strong buys,” while two recommended “buys” on the stock.
How Analysts Rated Jazz Pharmaceuticals in December
In December 2017, Jazz Pharmaceuticals (JAZZ) submitted a New Drug Application (or NDA) to the FDA for the approval of JZP-110.
Behind Jazz’s Strategic Collaboration with ImmunoGen
In August 2017, Jazz Pharmaceuticals (JAZZ) and ImmunoGen (IMGN) entered into a strategic collaboration and option agreement.
Jazz Pharmaceuticals on the Street: Analysts’ Recommendations after 1H17
In July 2017, Jazz Pharmaceuticals entered into a license agreement with XL-Protein GmbH involving products using XL-Protein’s PASylation technology.
What Jazz Pharmaceuticals Expects for Vyxeos
If Vyxeos manages to penetrate a sizeable portion of the target market, it may have a favorable impact on Jazz Pharmaceuticals stock.
How Jazz Pharmaceuticals Aims to Boost Vyxeos Sales in 2017
In early 2017, Jazz Pharmaceuticals (JAZZ) expanded its sales force team from 35 to 55 and expanded its field reimbursement teams to support the commercial launch of Vyxeos in the US.
Analysts’ Recommendations for Celgene in August 2017
Of the 27 analysts covering Celgene (CELG) in August 2017, 12 analysts recommended a “strong buy,” and ten analysts recommended a “buy.”
An Overview of Celgene’s Hematology and Oncology Pipeline
In December 2016, Celgene’s and Juno Therapeutics’ (JUNO) novel investigational drug, JCAR017, was given breakthrough designation by the US Food and Drug Administration (or FDA).
Agios Announces Data from Phase 2 Study of PK Deficiency
Agios Pharmaceuticals was one of the top performers among the small-cap segment within the iShares Nasdaq Biotechnology ETF (IBB) on June 13, 2016.
Agios Stock Rises on Higher Trading Volumes on June 8
Three analysts recommended a “buy” for Agios (AGIO), eight analysts recommended a “hold,” and no analysts recommended a “sell” for the stock. Agios has a weight of 2.2% in XBI’s portfolio.
XBI Remained Stable as the Markets Rallied on Higher Oil Prices
On June 8, the biotech and healthcare sectors had a mixed day and remained sluggish. The SPDR S&P Biotech ETF (XBI) gained 0.1% for the day. XBI has fallen by 16.4% on a year-to-date basis.
Agios Initiates Phase 1b Trial of AG-221 or AG-120: Stock Up 14%
Agios Pharmaceuticals (AGIO) stock rose 14% after it announced the initiation of the Phase 1b trial of either AG-221 or AG-120.
Small-Caps Are Topping the IBB Portfolio
Biotech stocks and ETFs had a good day on December 21 and rose marginally. The iShares Nasdaq Biotechnology ETF (IBB) rose 0.2% for the day and closed at $332.13.
BLUE Is IBB’s Worst-Performing Small-Cap on Disappointing Data
On December 7, 2015, bluebird bio (BLUE) fell 37.6%. The stock fell after it announced disappointing clinical data for its BB305 treatment.
IBB Falls as Energy Sector Negatively Influences the Market
The iShares Nasdaq Biotechnology ETF (IBB) fell by 2.3% and closed at $324.28, 5% lower than its 100-day moving average price of $341.38.
AbbVie, Lead Performer of the Pharmaceutical Subgroup
AbbVie (ABBV) rose 18.3% for the week ended October 30, 2015, and closed at $59.55. The stock went up on good 3Q15 earnings.
IBB Was among the Best Biotechnology ETFs for the Week
Biotechnology ETFs outperformed the broader market and posted some positive gains for the week. The iShares NASDAQ Biotechnology ETF gave a return of 2.9%.
Agios Outperformed: Rose 24.8% and Helped IBB Gain 3.2%
Agios Pharmaceuticals (AGIO) rose by a staggering 24.8% on October 27, 2015. It was the top performer in IBB’s portfolio.
